FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...
Precigen’s Strategic Advancements and FDA Alignment Bolster Buy Rating
Analyst Jason Butler of JMP Securities reiterated a Buy rating on Precigen (PGEN – Research Report), with a price target of $7.00. Jason ...
Strategic Market Position and FDA Milestone Propel Unicycive Therapeutics to ‘Buy’ Rating
Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Unicycive Therapeutics (UNCY – Research Report), with a price target of ...
Medicare Special Needs Plans Are Booming In Popularity. Are You Missing Out?
Medicare Advantage Special Needs Plans now make up more than a quarter of all enrollments. Learn more about what they are and ...